What If Diazoxide Fails for Congenital Hyperinsulinism?

When diazoxide is not effective at keeping your child’s blood sugar in a safe range, the standard second-line medical treatment involves a class of medications called somatostatin analogs, with octreotide being the most common ^[1]. If these second-line medications also fail to stabilize blood sugar, or if specialized imaging reveals a curable area in the pancreas, your care team will likely recommend surgical evaluation ^[1].

What Are Somatostatin Analogs?

Somatostatin analogs work by directly inhibiting the pancreas from releasing insulin. The two primary medications used for congenital hyperinsulinism (CHI) are:

• Octreotide: A short-acting medication that is typically given through multiple daily subcutaneous (under the skin) injections—usually 2 to 4 times a day ^[1]. Alternatively, it can be delivered continuously using a small, wearable infusion pump, similar to the devices used for type 1 diabetes ^[1].
• Lanreotide (and Octreotide LAR): These are longer-acting formulations given as a single injection once a month ^[1]. They carry a similar side effect profile to daily octreotide but are often considered for older infants and children to improve quality of life by reducing the number of daily needle pokes.

Important Note on Tachyphylaxis: While these medications can be very effective initially, a phenomenon known as tachyphylaxis (a rapid decrease in how well the drug works) occurs in about 18% of patients within the first few days or weeks of starting therapy ^[2]. Because of this risk, your care team will instruct you to check your child’s blood sugar very frequently during the first few weeks of treatment to catch any sudden drops and prevent dangerous lows.

Side Effects to Watch For

Because somatostatin analogs affect how multiple hormones and digestive enzymes are released, they come with unique side effects that require close monitoring. These apply to both short-acting and long-acting forms:

• Digestive Issues: Mild stomach upset, abdominal pain, and stool changes (like diarrhea or oily stools) are common but generally improve on their own within a few weeks of starting treatment ^[2]. However, if diarrhea is severe, persists, or your child shows signs of dehydration (like fewer wet diapers), contact your care team immediately.
• Gallbladder Issues: Approximately 32% of children treated with octreotide develop gallbladder sludge or gallstones ^[2]. While many children never show symptoms, your doctor will likely order a gallbladder ultrasound every 6 months to monitor for this ^[1].
• Growth Suppression: These medications can partially block the release of growth hormone. Mild slowing of growth is seen in about 13.5% of children on this therapy, though severe growth suppression is rare, affecting less than 5% ^[2]. Regular check-ins with a pediatric endocrinologist will track your child’s height, weight, and liver function to ensure they are thriving ^[1][2].
• Severe Complications in Newborns: In rare cases, particularly in premature infants or those treated in their first month of life, octreotide has been linked to a serious intestinal condition called necrotizing enterocolitis (NEC) ^[2]. Seek emergency medical care immediately if your baby develops a swollen, red, or tender belly, bloody stools, or green-tinged vomit.

When Is Surgery the Next Step?

Medical management is only successful if it can keep your child’s blood sugar consistently safe. Surgical evaluation becomes the immediate next step if:

1. Medical therapy fails: If even high doses of octreotide cannot prevent dangerous drops in blood sugar, preventing safe fasting or overnight glucose control ^[1].
2. A focal lesion is identified: If genetic testing and specialized imaging (like an 18F-DOPA PET scan) show that the excessive insulin is coming from one isolated spot (a focal lesion) rather than the whole pancreas. In these cases, surgically removing just that small piece of the pancreas can completely cure the condition ^[1].

Note: Both specialized imaging and pancreatic surgery for CHI are highly complex procedures. Your doctor will likely refer you to a dedicated, high-volume congenital hyperinsulinism center if surgery is being considered.